MindMed Joins Clinical Trials Transformation Initiative

MindMed (NASDAQ: MNMD) (NEO: MMED), a leading biotech company developing psychedelic-inspired therapies, has joined the Clinical Trials Transformation Initiative (CTTI) to contribute in developing and driving adoption of practices that increase the quality and efficiency of clinical trials.

MindMed joins CTTI as one of approximately 80 member organizations interested in advancing higher quality clinical trials and accelerating the path to new therapeutics and other medical products. CTTI convenes its members – along with nearly 500+ multi-stakeholder organizations and individuals from across the clinical trials ecosystem – to discuss issues, exchange ideas, and come to a consensus on solutions to the greatest challenges in clinical research. As a member of the Steering Committee, MindMed will contribute to setting project priorities within CTTI’s agenda, as well as serving on the teams that create recommendations and resources to transform clinical trials globally.

We welcome every meaningful opportunity to actively participate in the advancement of innovations that are ultimately contributing to the improvement of the way we develop medicine and bring treatment to the patient. MindMed and CTTI are both focused on improving clinical trials on behalf of patients and thus being a part of their mission aligns perfectly with the goals and values we have at MindMed. We look forward to being active partners in this initiative.

Daniel R. Karlin, MD MA, Chief Medical Officer of MindMed

CTTI’s Transforming Trials 2030 vision centers on five principles: that clinical trials in 2030 be patient-centered and easily accessible; fully integrated into health processes; designed with a quality approach; maximally leveraging all available data; and improving population health.

MindMed is working to increase accessibility to potentially curative therapies in an overburdened mental healthcare system, working to make sure adoption of psychedelic therapies is evidence-based and easy to integrate into existing healthcare processes. With their digital arm, Albert, MindMed uses traditional and digital clinical trial data collection tools to get patient-reported, clinician-reported, and real world data.

To view the original press release in its entirety click here

You might also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More